Noffar Bar, MD, Yale School of Medicine, New Haven, CT, comments on the key barriers that must be overcome in order to develop a cure for multiple myeloma (MM) and improve the outcomes of patients with the disease. Despite progress in immunomodulatory drugs (IMiDs), anti-CD38 antibodies, CAR-T, and bispecific antibodies, Dr Bar notes that treating higher-risk patients and eliminating measurable residual disease (MRD) remain barriers. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть